Integrin αvβ3 and LHRH Receptor Double Directed Nano-Analogue Effective Against Ovarian Cancer in Mice Model

References

• Chan JK, Kesterson JP, Richardson MT, et al. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: an NRG/GOG ancillary study. Gynecologic Oncol. 2022;167(3):429–435. doi:10.1016/j.ygyno.2022.09.028
   PubMed Web of Science ®Google Scholar
• Mailliez A, Pigny P, Bogart E, et al. Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients. Int J Cancer. 2022;150(11):1850–1860. doi:10.1002/ijc.33933
   PubMed Web of Science ®Google Scholar
• Kim SI, Kim JH, Lee S, et al. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a meta-analysis. Gynecol Oncol. 2022;167(3):547–556. doi:10.1016/j.ygyno.2022.10.010
   PubMed Web of Science ®Google Scholar
• Huang H, Dong Y, Zhang Y, et al. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer. Theranostics. 2019;9(4):1047–1065. doi:10.7150/thno.29820
   PubMed Web of Science ®Google Scholar
• Ye H, Liu X, Sun J, Zhu S, Zhu Y, Chang S. Enhanced therapeutic efficacy of LHRHa-targeted brucea javanica oil liposomes for ovarian cancer. BMC Cancer. 2016;16(1):831. doi:10.1186/s12885-016-2870-4
   PubMedGoogle Scholar
• Dharap SS, Wang Y, Chandna P, et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci USA. 2005;102(36):12962–12967. doi:10.1073/pnas.0504274102
   PubMed Web of Science ®Google Scholar
• He Y, Zhang L, Song C. PEGylated liposomes modified with LHRH analogs for tumor targeting. J Control Release. 2011;152:e29–31. doi:10.1016/j.jconrel.2011.08.103
   PubMed Web of Science ®Google Scholar
• Linhua Z, Yanqing R, Yong W, Yingna H, Wei F, Cunxian S. Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide. Int J Nanomed. 2018;13:1097–1105. doi:10.2147/IJN.S150512
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhou X, Feng W, Pu T, Xu C. Gonadotropin-releasing hormone receptor-targeted near-infrared fluorescence probe for specific recognition and localization of peritoneal metastases of ovarian cancer. Front Oncol. 2020;10:10. doi:10.3389/fonc.2020.00010
   PubMed Web of Science ®Google Scholar
• Sundaram S, Kadam R, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther. 2009;8(6):1655–1665. doi:10.1158/1535-7163.MCT-08-0988
   PubMed Web of Science ®Google Scholar
• He Y, Zhang L, Song C. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes. Int J Nanomed. 2010;5:697–705. doi:10.2147/ijn.s12129
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ji Y. RGD-modified polymer and liposome nanovehicles: recent research progress for drug delivery in cancer therapeutics - ScienceDirect. Eur J Pharm Sci. 2019;128:8–17. doi:10.1016/j.ejps.2018.11.023
   PubMed Web of Science ®Google Scholar
• Song Y, Guo X, Fu J, et al. Dual-targeting nanovesicles enhance specificity to dynamic tumor cells in vitro and in vivo via manipulation of αvβ3-ligand binding. Acta Pharmaceutica Sinica B. 2020;11(10):2183–2197. doi:10.1016/j.apsb.2020.07.012
   Google Scholar
• Qi N, Zhang S, Zhou X, et al. Combined integrin αvβ3 and lactoferrin receptor targeted docetaxel liposomes enhance the brain targeting effect and anti-glioma effect. J Nanobiotechnol. 2021;19(1):446. doi:10.1186/s12951-021-01180-0
   PubMed Web of Science ®Google Scholar
• Faria RS, De lima LI, Bonadio RS, et al. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer. Biomed Pharmacother. 2021;142:112000. doi:10.1016/j.biopha.2021.112000
   PubMed Web of Science ®Google Scholar
• Tang Z, Feng W, Yang Y, Wang Q. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies. Drug Des Devel Ther. 2019;13:3281–3290. doi:10.2147/DDDT.S211168
   PubMed Web of Science ®Google Scholar
• Pu C, Chang S, Sun J, Zhu S, Xu RX. Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles for the treatment of intraperitoneal ovarian cancer xenografts. Mol Pharm. 2014;11(1):40–48. doi:10.1021/mp400523h
   PubMedGoogle Scholar
• Kang S, Duan W, Zhang S, Chen D, Qi N, Qi N. Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma. Theranostics. 2020;10(10):4308–4322. doi:10.7150/thno.41322
   PubMed Web of Science ®Google Scholar
• Qi N, Zhang Y, Tang X, Li A. Cationic/Anionic Polyelectrolyte (PLL/PGA) Coated Vesicular Phospholipid Gels (VPGs) Loaded with Cytarabine for Sustained Release and Anti-glioma Effects. Drug Des Devel Ther. 2020;14:1825–1836. doi:10.2147/DDDT.S248362
   PubMed Web of Science ®Google Scholar
• Wei M, Xu Y, Zou Q, et al. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur J Pharm Sci. 2012;46(3):131–141. doi:10.1016/j.ejps.2012.02.007
   PubMed Web of Science ®Google Scholar
• Yuan WM, Song QG, Zhang ZR, Fu Y, He Q, He Q. LHRHa aided liposomes targeting to human ovarian cancer cells: preparation and cellular uptake. Pharmazie. 2008;63(6):434–438.
   PubMed Web of Science ®Google Scholar
• Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. BBA. 1995;1239(2):133–144. doi:10.1016/0005-2736(95)00138-S
   PubMed Web of Science ®Google Scholar
• Kushwah V, Jain DK, Agrawal AK, Jain S. Improved antitumor efficacy and reduced toxicity of docetaxel using anacardic acid functionalized stealth liposomes. Colloids and surfaces. Biointerfaces. 2018;172:213–223. doi:10.1016/j.colsurfb.2018.08.047
   PubMed Web of Science ®Google Scholar
• Zou L, Liu X, Li J, Li W, Gu Z. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy. Theranostics. 2021;11(9):4171–4186. doi:10.7150/thno.42260
   PubMed Web of Science ®Google Scholar
• Zuo H. iRGD: a promising peptide for cancer imaging and a potential therapeutic agent for various cancers. J Oncol. 2019;2019:9367845. doi:10.1155/2019/9367845
   PubMed Web of Science ®Google Scholar
• Guo Z, Li S, Liu Z, Xue W. Tumor-penetrating peptide-functionalized redox-responsive hyperbranched Poly(amido amine) delivering siRNA for lung cancer therapy. ACS Biomater Sci Eng. 2018;4(3):988–996. doi:10.1021/acsbiomaterials.7b00971
   PubMed Web of Science ®Google Scholar
• Rui R, Wang H, Yun L. Microfluidic self-assembly of a combinatorial library of single- and dual-ligand liposomes for in vitro and in vivo tumor targeting. Eur J Pharm Biopharm. 2018;2(3):243–257.
   Google Scholar
• Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating colocalization in biological microscopy. Am J Physiol. 2011;300(4):C723–742. doi:10.1152/ajpcell.00462.2010
   PubMed Web of Science ®Google Scholar
• Tzaban S, Massol RH, Yen E, et al. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol. 2009;185(4):673–684. doi:10.1083/jcb.200809122
   PubMed Web of Science ®Google Scholar
• Wei L, Guo XY, Yang T, Yu MZ, Chen DW, Wang J-C. Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles. Int J Pharm. 2016;510(1):394–405. doi:10.1016/j.ijpharm.2016.06.127
   PubMed Web of Science ®Google Scholar
• Li F, Lu J, Liu J, et al. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nat Commun. 2017;8(1):1390. doi:10.1038/s41467-017-01565-6
   PubMedGoogle Scholar